Genetic Counseling for Lysosomal Storage Diseases

  • Erin O'Rourke
  • Dawn Laney
  • Cindy Morgan
  • Kim Mooney
  • Jennifer Sullivan

In many ways, the role of the genetic counselor working with patients and families with a lysosomal storage disease is similar to a counselor in other pediatric and adult counseling situations. The goals of counseling; education, access to health care, and supportive counseling are the same. Although the goals of counseling are simply stated, an effective counseling session is always a complex interaction. It is an empathic exchange where the counselor promotes understanding of the particular disease, the inheritance pattern, takes a family history, provides recurrence risks, and reviews diagnostic testing, disease management issues, and supportive resources, while simultaneously learning about family structure, dynamics, and the impact of the diagnosis. The counselor assesses the level of understanding about the disease and the appropriate resources to assist the patient and family facing an inherited disease. A balance of teaching and counseling and the ability to be flexible and responsive to the counselee is key for achieving an effective interaction. The chapter is designed as a resource for counselors or other health care providers interested in an update on counseling issues for this group of treatable lysosomal storage diseases. Six genetic counselors who have been involved with the lysosomal storage disease community for the last decade draw on their counseling expertise to provide a disease summary and clinical counseling pearls for Gaucher disease, Fabry disease, Mucopolysaccharidosis (MPS) type 1, MPS II, MPS VI, and Pompe disease.


Genetic Counseling Enzyme Replacement Therapy Fabry Disease Gauche Disease Pompe Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amartino, H. Painceira, D. Pomponio, R.J. Niizawa, G. Sabio Paz, V. Blanco, M.A. Chamoles, N.A. (2006). Two clinical forms of glycogen-storage disease type II in two generations of the same family. Clin Genet 69:187-188.CrossRefPubMedGoogle Scholar
  2. An, Y. Young, S.P. Kishnani, P.S. Millington, D.S. Amalfitano, A. Corzo, D. Chen, Y.T. (2005). Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab 85:247-254.CrossRefPubMedGoogle Scholar
  3. Ausems, M.G. Verbiest, J. Hermans, M.P. Kroos, M.A. Beemer, F.A. Wokke, J.H. Sandkuijl, L.A. Reuser, A.J. van der Ploeg, A.T. (1999). Frequency of glycogen storage disease type II in The Netherlands: Implications for diagnosis and genetic counselling. Eur J Hum Genet 7:713-716.CrossRefPubMedGoogle Scholar
  4. Barranger, J.A. Ginns, E.I. (1989) Glucosylceramide lipidosis: Gaucher disease. In: Scriver, C.R. Beaudet, A. Sly, W.S. Valle, D. (Eds). The Metabolic Basis of Inherited Disease. 6th ed. New York: McGraw-Hill; pp. 1677-1698.Google Scholar
  5. Barranger, J.A. O’Rourke, E. (2001). Lessons learned from the development of enzyme replacement therapy for Gaucher disease. J Inherit Metab Dis 24 Supp 2:87-96.CrossRefGoogle Scholar
  6. Bennett, R.L, Hart, K. O’Rourke, E, Barranger, J.A. Johnson, J, MacDermot, K.D. Pastores, G.M. Steiner R.D. Tadhani R. (2002). Fabry Disease in Genetic Counseling Practice: Recommendations of the National Society of genetic Counselors. J Genet Counsel. 11:121-146.CrossRefGoogle Scholar
  7. Brady, R.O. Grabowski, G.A. Thadhani, R. (2000). Fabry disease: α-galactosidase A deficiency. Gardiner-Caldwell SynderMed 1-8.Google Scholar
  8. Brady, R.O. Murray, G.J. Moore, D.F. Schiffmann, R. (2001). Enzyme replacement therapy in Fabry disease. J Inher Metab Dis 24 Supp 2:18-24.CrossRefPubMedGoogle Scholar
  9. Case, L.E. Kishnani, P.S. (2006). Physical therapy management of Pompe disease. Genet Med 8:318-327.PubMedCrossRefGoogle Scholar
  10. Charrow, J. Andersson, H.C. Kaplan, P. Kolodny, E.H. Pastores, G.M. et al. (2004). Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: Consensus recommendations. J Pediatr 144:112-120.CrossRefPubMedGoogle Scholar
  11. Cox, T. Lachmann, R. Hollak, C. Aerts, J. van Weely, S. Hrebicek, M. Platt, F.M, Butters, T.D Dwek, R. Moyses, C. Gow, I. Elstein, D. Zimran, A. (2000). Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet, 355:1481-1485.Google Scholar
  12. Damiano, A.M.Pastores, G.M. Ware, J.E. (1998) The health related quality of life of adults with Gaucher’s disease receiving enzyme replacement therapy: Results from a retrospective study. Qual Life Res 7:373-86.CrossRefPubMedGoogle Scholar
  13. Desnick, R.J. Brady, R.O. Barranger, J.A. Collins, A.J. Germain, D.P. Goldman, M. Grabowski, G.A. Packman, S. Wilcox, W.R. (2003). Fabry disease, an under-reco-gnized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338-346.PubMedGoogle Scholar
  14. Elstein, D. Hollak, C.E. Aerts, J.M. vanWeely, S. Maas, M. Cox, T.M. Lachmann, R.H. Hrebicek, M. Platt, F.M. Butters, T.D. Dwek, R.A. Zimran, A. (2004). Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 27:757-766.CrossRefPubMedGoogle Scholar
  15. Eng, C.M. Guffon, N. Wilcox, W.R. Germain, D.P, Lee, P. Waldek, S. Caplan, L. Linthorst, G.E. Desnick, R.J. (2001). Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry’s disease. N Eng J Med 345: 9-16.CrossRefGoogle Scholar
  16. Grabowski, G.A. Beutler, E. (2001). Gaucher disease. In: Scriver C, Beaudet A, Sly W, Valle D, Childs B, Kinzler K (Eds). The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; pp. 3635-3638.Google Scholar
  17. Grewal SS, Wynn R, Abdenur JE, Burton BK, Gharib M, Haase C, Hayashi RJ, Shenoy S, Sillence D, Tiller GE, Dudek ME, van Royen-Kerkhof A, Wraith JE, Woodard P, Young GA, Wulffraat N, Whitley CB, Peters C. (2005). Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med 7: 143-146.PubMedCrossRefGoogle Scholar
  18. Hagemans, M.L. Janssens, A.C. Winkel, L.P. Sieradzan, K.A. Reuser, A.J. Van Doorn, P.A. Van der Ploeg, A.T. (2004). Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology 63:1688-1692.PubMedGoogle Scholar
  19. Hagemans, M.L. Winkel, L.P. Hop, W.C. Reuser, A.J. Van Doorn, P.A. Van der Ploeg, A.T. (2005). Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 64:2139-2141.CrossRefPubMedGoogle Scholar
  20. Harmatz, P. Ketteridge, J. Giugliani, R. Guffon, N. Teles, E. Miranda, S, Swiedler, S. Hopwood, J.J. (2005). Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115, e681-e689.CrossRefPubMedGoogle Scholar
  21. Harmatz, P. Whitley, C.B. Waber, L. Pais, R. Steiner, R. Plecko, B. Kaplan, P. Simon, J. Butensky, E. Hopwood, J.J. (2004). Enzyme replacement therapy in mucopoly-saccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 144(5):574-580.CrossRefPubMedGoogle Scholar
  22. Hermans, M.M. van Leenen, D. Kroos, M.A. Beesley, C.E. Van Der Ploeg, A.T. Sakuraba, H. Wevers, R. Kleijer, W. Michelakakis, H. Kirk, EP. Fletcher, J. Bosshard, N. Basel-Vanagaite, L. Besley, G. Reuser, A.J. (2004). Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat 23:47-56.CrossRefPubMedGoogle Scholar
  23. Hoefsloot, L.H. van der Ploeg, A.T. Kroos, M.A. Hoogeveen-Westerveld, M. Oostra, B.A. Reuser, A.J. (1990). Adult and infantile glycogenosis type II in one family, explained by allelic diversity. Am J Hum Genet 46:45-52.PubMedGoogle Scholar
  24. Kakkis E, McEntee M, Vogler C, Le S, Levy B, Belichenko P, Mobley W, Dickson P, Hanson S, Passage M. (2004). Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I, Mol Genet Metab 83:163-174.CrossRefPubMedGoogle Scholar
  25. Kishnani, P. Corzo, D. Nicolino, M. Byrne, B. Mandel, H. Hwu, W.L. Leslie, N. Levine, J. Spencer, C. McDonald, M. Li J, DuMontier, J. Michael, H. Chien, Y.H. Hopkin, R. Vijayaraghavan, S. Gruskin, D. Bartholomew, D. van der Ploeg, A. Clancy, J.P. Parini, R. Morin, G. Beck, M. Delagastine, G. S. Jokic, M. Thurberg, B. Richards, S. Bali, D. Davison, M. Worden, M. Chen, Y.T. Wraith, J.E. (2007). Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease. Neurology 68:99-109.CrossRefPubMedGoogle Scholar
  26. Kishnani, P.S. Howell, R.R. (2004). Pompe disease in infants and children. J Pediatr 144:S35-43.CrossRefPubMedGoogle Scholar
  27. Kishnani, P.S. Hwu, W.L. Mandel, H. Nicolino, M. Yong, F. Corzo, D. (2006). A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671-676.CrossRefPubMedGoogle Scholar
  28. Kishnani, P.S. Steiner, R.D. Bali, D. Berger, K. Byrne, B.J. Case, L.E. Crowley, J.F. Downs, S. Howell, R.R. Kravitz, R.M. Mackey, J. Marsden, D. Martins, A.M. Millington, D.S. Nicolino, M. O’Grady, G. Patterson, M.C. Rapoport, D.M. Slonim, A. Spencer, C.T. Tifft, C.J. Watson, M.S. (2006). Pompe disease diagnosis and management guideline. Genet Med 8:267-288.PubMedCrossRefGoogle Scholar
  29. Li, Y. Scott, C.R. Chamoles, N.A. Ghavami, A. Pinto, B.M. Turecek, F. Gelb, M.H. (2004). Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 50:1785-1796.CrossRefPubMedGoogle Scholar
  30. Litjens, T. Hopwood, J.J. (2001) Mucopolysaccharidosis type VI: Structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase. Hum Mutat 18:282-295.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Erin O'Rourke
    • 1
  • Dawn Laney
    • 2
  • Cindy Morgan
    • 3
  • Kim Mooney
    • 4
  • Jennifer Sullivan
    • 5
  1. 1.Department of Human GeneticsUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Emory Lysosomal Storage Disease CenterEmory UniversityAtlantaUSA
  3. 3.Stanford Lysosomal Disease CenterUniversity of California San FranciscoSan FranciscoUSA
  4. 4.Genetic CounselingBiomarin PharmaceuticalNovatoUSA
  5. 5.Metabolic ClinicDuke University Medical CenterDurhamUSA

Personalised recommendations